Anesthetic Effect-Pipeline Review, H2 2017

Anesthetic Effect-Pipeline Review, H2 2017


  • Products Id :- GMDHC9705IDB
  • |
  • Pages: 88
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Anesthetic Effect-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect-Pipeline Review, H2 2017, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape.

Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of adverse reactions to anesthesia and drug allergies.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Anesthetic Effect-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Anesthetic Effect (Central Nervous System)

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Anesthetic Effect (Central Nervous System) pipeline guide

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 The guide covers therapeutics under Development by Companies /Universities /Institutes,

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017

Anesthetic Effect (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is

List of TablesNumber of Products under Development for Anesthetic Effect, H2 2017 10Number of Products under Development by Companies, H2 2017 Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Anesthetic Effect (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Anesthetic Effect (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Anesthetic Effect (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Anesthetic Effect (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Anesthetic Effect (Central Nervous System)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Anesthetic Effect (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Anesthetic Effect (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anesthetic Effect-Overview

Anesthetic Effect-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anesthetic Effect-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anesthetic Effect-Companies Involved in Therapeutics Development

4P Therapeutics LLC

Biolab Farmaceutica Ltda

Crescita Therapeutics Inc

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Jiangsu Hengrui Medicine Co Ltd

Lee's Pharmaceutical Holdings Ltd

Lipicard Technologies Ltd

Paion AG

Phosphagenics Ltd

Physica Pharma

Primex Pharmaceuticals Oy

Proteus SA

Recro Pharma Inc

Taiwan Liposome Company Ltd

The Medicines Company

Anesthetic Effect-Drug Profiles

alphaxalone-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Aom-0765-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bupivacaine hydrochloride SR-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Carboetomidate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cysteine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXPS-09-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Flexicaine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gabafol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HSK-3486-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1121-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1123-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Methoxycarbonyl Carboetomidate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Methoxycarbonyl Etomidate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midazolam hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

neosaxitoxin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PB-5109-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PHY-301-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

propofol-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

remimazolam-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-1000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-2000-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Anesthetic Effect-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NMDA Receptor for Anesthesia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPR-819-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Anesthetic Effect-Dormant Projects

Anesthetic Effect-Discontinued Products

Anesthetic Effect-Product Development Milestones

Featured News & Press Releases

Mar 09, 2017: China FDA has Approved Zingo for Pediatric Use Needle-free Local Analgesia as Priority Review for Clinical Trial

Nov 14, 2016: Powder Pharmaceuticals Submits New Drug Application to China FDA and Hong Kong Department of Health for Needle-free Local Analgesia

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy

Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment

Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy

Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015

Sep 01, 2015: Recently Published Study Shows Positive Results for ZiNGO in Pediatric Patients

Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia

Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy

Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States

Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Anesthetic Effect, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

List of Tables

Number of Products under Development for Anesthetic Effect, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Anesthetic Effect-Pipeline by 4P Therapeutics LLC, H2 2017

Anesthetic Effect-Pipeline by Biolab Farmaceutica Ltda, H2 2017

Anesthetic Effect-Pipeline by Crescita Therapeutics Inc, H2 2017

Anesthetic Effect-Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2017

Anesthetic Effect-Pipeline by Expanesthetics Inc, H2 2017

Anesthetic Effect-Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017

Anesthetic Effect-Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Anesthetic Effect-Pipeline by Lipicard Technologies Ltd, H2 2017

Anesthetic Effect-Pipeline by Paion AG, H2 2017

Anesthetic Effect-Pipeline by Phosphagenics Ltd, H2 2017

Anesthetic Effect-Pipeline by Physica Pharma, H2 2017

Anesthetic Effect-Pipeline by Primex Pharmaceuticals Oy, H2 2017

Anesthetic Effect-Pipeline by Proteus SA, H2 2017

Anesthetic Effect-Pipeline by Recro Pharma Inc, H2 2017

Anesthetic Effect-Pipeline by Taiwan Liposome Company Ltd, H2 2017

Anesthetic Effect-Pipeline by The Medicines Company, H2 2017

Anesthetic Effect-Dormant Projects, H2 2017

Anesthetic Effect-Discontinued Products, H2 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

4P Therapeutics LLC

Biolab Farmaceutica Ltda

Crescita Therapeutics Inc

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Jiangsu Hengrui Medicine Co Ltd

Lee's Pharmaceutical Holdings Ltd

Lipicard Technologies Ltd

Paion AG

Phosphagenics Ltd

Physica Pharma

Primex Pharmaceuticals Oy

Proteus SA

Recro Pharma Inc

Taiwan Liposome Company Ltd

The Medicines Company

Anesthetic Effect Therapeutic Products under Development, Key Players in Anesthetic Effect Therapeutics, Anesthetic Effect Pipeline Overview, Anesthetic Effect Pipeline, Anesthetic Effect Pipeline Assessment

select a license
Single User License
USD 2000 INR 138420
Site License
USD 4000 INR 276840
Corporate User License
USD 6000 INR 415260

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com